

Independent Auditor's examination report on Restated Financial Information

To,
The Board of Directors of,
INFLUX HEALTHTECH LIMITED
Formerly known as (Influx HealthTech Private Limited)

Dear Sir (s),

1. We have examined the attached Restated Financial Statements of **INFLUX HEALTHTECH LIMITED** (formerly known as **Influx HealthTech Private Limited**) (the "Company") comprising the Restated Statement of Assets and Liabilities as at **30th November 2024, 31st March 2024, 31st March 2023 and 31st March 2022**, the Restated Statements of Profit and Loss, the Restated Cash Flow Statement for 8 months period ended 30th November 2024, and for the financial years ended 31st March 2024, 31st March 2023, and 31st March, 2022, the Summary Statement of Significant Accounting Policies and the Notes to Accounts as forming part of these Restated Financial Statements (collectively, the "Restated Financial Information"), as approved by the Board of Directors of the Company at their meeting held on January 20, 2025 for the purpose of inclusion in the Draft Red Herring Prospectus / Red Herring Prospectus / Prospectus as the case may be ("Offer Documents"). These restated financial statements have been prepared by the management of the Company in connection with its proposed SME Initial Public Offer of equity shares ("SME IPO").

2. These restated financial information have been prepared in accordance with the terms of requirements of:

- a) Section 26 of Part I of Chapter III of the Companies Act, 2013 (the "Act") read with Companies (Prospectus and Allotment of Securities) Rules 2014;
- b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") and related amendments/clarifications from time to time issued by the Securities and Exchange Board of India ("SEBI"); and
- c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended from time to time (the "Guidance Note").



3. The Company's Board of Directors is responsible for the preparation of the Restated Financial Information for the purpose of inclusion in the Offer Documents to be filed with SEBI, relevant stock exchange and Registrar of Companies, Mumbai in connection with the proposed SME IPO. The Restated Financial Information has been prepared by the management of the Company on the basis of preparation stated in summary of significant accounting policies to the Restated Financial Information.

The Board of Directors responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Financial Information. The Board of Directors is also responsible for identifying and ensuring that the Company complies with the Act, ICDR Regulations and the Guidance Note.

4. We, V.B Goel & Co., Chartered Accountants have been subjected to the peer review process of the Institute of Chartered Accountants of India ("ICAI") and holds the peer review certificate dated 13.04.2023 valid till 31.03.2026.

5. We have examined such restated financial information taking into consideration:

a) The terms of reference and terms of our engagement agreed upon with you in accordance with our engagement letter dated December 30, 2024 in connection with the proposed SME Initial Public Offering of equity shares of the company;

b) The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI;

c) Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Financial Information; and

d) The requirements of Section 26 of the Act and the ICDR Regulations. Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the SME IPO.

6. The restated financial statements of the company have been compiled by the management from the audited financial statements of the Company as at and for the Stub period ended November 30, 2024 and financial year ended on March 31 2024, March 31 2023 and March 31 2022 prepared in accordance with the Accounting Standards as prescribed under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014, as amended, and other accounting principles generally accepted in India and which have been approved by the board of directors.



7. For the purposes of examination, we have relied on:

- a) Auditors' Report issued by us for the period ended November 30, 2024 and for the financial year ended March 31, 2024.
- b) Auditors' reports issued by Company's previous auditors, Phirodia Bafna & Associates for the financial year ended March 31, 2023 and March 31, 2022 and accordingly reliance has been placed on financial information examined by them for the said years. The financial report included for these years is based solely on the report submitted by them.

8. Based on our examination and according to the information and explanations given to us and as per the reliance placed on the audit report submitted by the Previous Auditors for the respective year, we report that the Restated Financial Information:

- a) Have been prepared after incorporating adjustments for the changes in accounting policies, material errors and regrouping/reclassifications retrospectively for 8 months period ended on 30th November 2024 and financial year ended 31st March 2024, 31st March 2023 and March 31st 2022 to reflect the same accounting treatment as per the accounting policies and grouping/ classifications followed for the period ended 30th November 2024;
- b) There are no audit qualifications in the audit reports issued by the statutory auditors for the period ended on November 30, 2024 and financial year ended on March 31 2024, March 31 2023 and March 31 2022 which would require adjustments in the restated financial statements of the Company and
- c) Have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.

9. In accordance with the requirements of the Act including the rules made thereunder, ICDR Regulations, Guidance Note and Engagement Letter, we report that :

- a) The "restated statement of assets and liabilities" of the Company as at Nov 30 2024, March 31 2024, March 31 2023 and March 31 2022 examined by us, read with significant accounting policies have been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this report.



b) The “**restated statement of profit and loss**” of the Company for the 8 months period ended on Nov 30 2024 and financial year ended on March 31 2024, March 31 2023 and March 31 2022 examined by us, read with significant accounting policies have been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this report.

c) The “**restated statement of cash flows**” of the Company for the 8 months period ended on Nov 30 2024 and financial year ended on March 31 2024, March 31 2023 and March 31 2022 examined by us, read with significant accounting policies have been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this report.

10. In our opinion, the restated financial information comprising the restated statement of assets and liabilities, the restated statement of profit and loss and the restated cash flow statement read with the summary statement of significant accounting polices and notes to the restated financial statement, examined by us, are prepared after making such adjustments and regroupings as considered appropriate and have been prepared in accordance with the Act, ICDR Regulations, Engagement Letter and Guidance Note and give a true and fair view in conformity with the accounting principles generally accepted in India, to the extent applicable.

11. This report should not in any way be construed as a reissuance or re-dating of any of the previous audit reports issued by us or the Previous Auditors, nor should this report be construed as a new opinion on any of the financial statements referred to herein.

12. We have no responsibility to update our report for events and circumstances occurring after the date of the report.

13. In our opinion, the restated financial statements are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with the Act, ICDR Regulations, Engagement Letter and Guidance Note.

14. Our report is intended solely for use of the Board of Directors for inclusion in the Offer Documents to be filed with SEBI, relevant stock exchange and Registrar of Companies, Mumbai in connection with the proposed SME IPO. Our report should not be used, referred to, or distributed for any other purpose except with our prior consent in writing. Accordingly, we do not accept or assume



any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W



VBS

(Vikas Goel)
Partner

Membership No. : 39287
UDIN: 25039287BMMIYN3753

Place : Mumbai
Date : 20-01-2025

(Formerly known as Influx Healthtech Private Limited)
Restated Statement of Assets & Liabilities

(Rs. in lakhs, unless otherwise stated)

Particulars	Note No.	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
EQUITY AND LIABILITIES					
1. Shareholders' fund					
(a) Share Capital	2	1,815.00	2.50	2.50	2.50
(b) Reserves and Surplus	3	1,276.72	2,284.72	1,162.65	443.01
2. Non-Current Liabilities					
(a) Long-Term Borrowings	4	-	-	3.29	7.85
(b) Deferred Tax Liabilities (Net)	5	-	-	1.39	2.80
(c) Other Long-Term Liabilities	6	5.26	5.26	5.26	-
(d) Long Term Provision	7	-	28.66	16.27	6.81
3. Current Liabilities					
(a) Short Term Borrowing	8	26.74	29.19	72.00	49.00
(b) Trade Payables	9	-	-	-	-
- Dues to Micro, Small and Medium Enterprises ('MSME')		688.93	387.07	221.66	113.81
- Dues to Creditors Other than MSMEs		1,496.54	1,049.47	1,123.82	989.67
(c) Other Current Liabilities	10	256.96	172.05	192.55	116.51
(d) Short-term Provisions	11	130.34	151.38	29.03	26.87
TOTAL		5,696.50	4,110.31	2,830.42	1,758.84
ASSETS					
1. Non-Current Assets					
(a) Property, Plant & Equipment and Intangible Assets	12	-	-	-	-
- Property, plant & Equipment		1,619.98	1,370.60	629.64	274.11
Intangible assets		1.97	2.39	3.22	-
(b) Deferred Tax Asset (Net)	13	4.96	28.56	-	-
(c) Long term loans and advances	14	221.58	140.58	191.24	102.33
(d) Other non current assets	15	0.44	-	-	-
2. Current Assets					
(a) Inventories	16	665.33	545.62	196.19	175.49
(b) Trade receivables	17	2,647.28	1,591.60	1,382.51	1,031.06
(c) Cash and Bank balance	18	340.00	360.56	354.71	146.52
(d) Short-term loans and advances	19	138.39	68.31	72.93	29.31
(e) Other current assets	20	56.58	2.09	-	-
TOTAL		5,696.50	4,110.31	2,830.42	1,758.84

Notes to Accounts forming integral part of financial statements 01-44

As per our attached report of even date.

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO

Chartered Accountants

Firm Registration No.: 115906W

Vikas Goel
Partner
Membership. No. 39287
Place: Mumbai
Date: 20/01/2025



M. A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN: 08459582
Place: Mumbai
Date: 20/01/2025

Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date: 20/01/2025

Shirin Chandniwala

Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place: Mumbai
Date: 20/01/2025

Atul Shukla
(Company Secretary)
Membership Number : ACS46854

Place: Mumbai
Date: 20/01/2025

(Formerly known as Influx Healthtech Private Limited)
Restated Statement of Profit & Loss

(Rs. in lakhs, unless otherwise stated)

Particulars	Note No.	For the period ended	For the period ended	For the period ended	For the period ended
		30 November, 2024	31 March, 2024	31 March, 2023	31 March, 2022
I. INCOME					
Revenue from Operations	22	6,274.92	9,996.51	7,605.65	5,920.17
Other Incomes	23	53.75	13.73	1.10	-
TOTAL INCOME		6,328.66	10,010.23	7,606.75	5,920.17
II. EXPENDITURE					
Cost of Materials Consumed	24	3,827.50	6,526.94	5,274.25	4,592.26
Changes in inventories	25	(5.03)	(37.01)	(2.42)	(39.43)
Employee Benefit Expenses	26	538.85	704.20	515.42	346.55
Financial Costs	27	0.44	5.89	5.99	4.18
Depreciation & Amortization	13	170.96	185.43	93.74	12.20
Other Expenses	28	726.59	1,115.00	746.14	403.81
TOTAL EXPENSES		5,259.31	8,500.45	6,633.12	5,319.58
III Net Profit before tax		1,069.35	1,509.78	973.63	600.59
IV Tax Expenses					
Current Tax		241.24	417.66	255.41	154.34
Deferred Tax		23.61	(29.96)	(1.41)	2.80
V. Net Profit after tax		804.50	1,122.08	719.63	443.45
VI Earning per Equity Share					
Basic (in Rs.)	30	4.43	6.18	3.96	2.44
Diluted (in Rs.)		4.43	6.18	3.96	2.44
Notes to Accounts forming integral part of financial statements	01-44				

As per our attached report of even date.

For V.B.GOEL & CO

Chartered Accountants

Firm Registration No.: 115906W

Vikas Goel

Partner

Membership. No. 39287

Place: Mumbai

Date: 20/01/2025



For and on behalf of the Board of Directors of Influx Healthtech Limited

Munir Chandniwala

Munir Chandniwala
(Managing Director)

DIN: 08459582

Place: Mumbai

Date: 20/01/2025

Shirin Chandniwala

Shirin Chandniwala
(Whole - Time Director)

DIN: 08459623

Place: Mumbai

Date: 20/01/2025



Ashish Shah

Ashish Shah
(Chief Financial Officer)

Place: Mumbai

Date: 20/01/2025

Atul Shukla

Atul Shukla
(Company Secretary)

Membership Number : ACS46854

Place: Mumbai

Date: 20/01/2025

(Formerly known as Influx Healthtech Private Limited)
Restated Cash Flow Statement

Particulars	For the period ended	For the period ended	For the period ended	For the period ended
	30 November, 2024	31 March, 2024	31 March, 2023	31 March, 2022
A) Cash Flow from Operating Activities				
Net Profit before tax & extraordinary items	1,069.35	1,509.78	973.63	600.59
Adjustment For :				
Depreciation & Amortization Expenses	170.96	185.43	93.74	12.20
Bad Debts Written Off	-	13.20	-	-
Provision for bad and doubtful debts	-	18.53	-	-
Reversal of provision for doubtful debts	(18.52)	-	-	-
Sundry Balances Written Off	(28.55)	(8.64)	-	-
Interest Expenses & other finance cost	0.44	5.89	0.93	0.49
Interest Income	(3.78)	(2.32)	-	-
Unrealised foreign exchange loss / (gain) (net)	-	(0.07)	-	-
Operating Profit Before Working Capital Changes	1,189.90	1,721.81	1,068.30	613.28
Adjusted for :				
Increase/(Decrease) in Trade payables	777.48	99.77	242.01	1,094.17
Increase/(Decrease) in Other Current Liabilities	84.91	(20.50)	76.04	71.97
Increase/(Decrease) in Provision	(49.70)	134.74	11.62	60.49
(Increase)/Decrease in Trade Receivables	(1,037.16)	(240.82)	(351.44)	(1,031.06)
(Increase)/Decrease in Inventories	(119.71)	(349.43)	(20.70)	(175.49)
(Increase)/Decrease in Loans and Advances	(151.08)	55.27	(132.52)	(10.74)
(Increase)/Decrease in Other Long Term Liabilities	-	-	5.26	-
(Increase)/Decrease in Other Current and Non-current Assets	(54.92)	(2.09)	-	(120.89)
Net Cash generated from Operating activities (before tax)	639.72	1,398.75	898.56	501.72
(Tax Paid)/ Tax Refund - Net	(241.24)	(417.66)	(255.40)	(127.47)
Net Cash Generated from Operating Activities (A)	398.48	981.09	643.16	374.25
B) Cash Flow from Investing Activities				
Purchase of Property, Plant and Equipment and Intangible Assets	(419.93)	(925.56)	(452.48)	(286.31)
Interest Income	3.78	2.32	-	-
Net Cash used in Investment Activities (B)	(416.15)	(923.24)	(452.48)	(286.31)
C) Cash Flow from Financing Activities				
Interest Expenses & other finance cost	(0.44)	(5.89)	(0.93)	(0.49)
(Repayment)/ Proceeds of Long Term Borrowings	-	(3.29)	(4.56)	56.83
(Repayment)/ Proceeds of Short Term Borrowings	(2.45)	(42.81)	23.00	-
Net cash generated from / (used in) Financing Activities (C)	(2.89)	(51.98)	17.51	56.34
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(20.56)	5.86	208.19	144.28
Cash and Cash Equivalents at the beginning of the Year				
Cash and cash equivalents	290.56	354.71	146.52	2.24
Short term bank deposits	70.00	-	-	-
Cash and Cash Equivalents at the end of the Year	340.00	360.57	354.72	146.52
Cash and cash equivalents comprise of:				
Cash on Hand	3.54	2.41	1.42	1.19
Bank Balances:				
In Current Accounts	266.45	288.16	353.28	145.34
Short Term Bank Deposit	70.00	70.00	-	-
Cash and cash equivalents at the end of the Year	340.00	360.56	354.72	146.52

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard - 3 on Cash Flow Statement issued by ICAI.

Previous year's figures have been regrouped where ever necessary to align with the current year's classification.

As per our attached report of even date.

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO

Chartered Accountants

Firm Registration No.: 115906W

WS
Vikas Goel
Partner
Membership No.39287
Place : Mumbai
Date : 20/01/2025



m.a. Chandniwal -
Munir Chandniwala
(Managing Director)
DIN: 08459582
Place : Mumbai
Date : 20/01/2025

Ajesh Shah
Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date : 20/01/2025

sm Chandniwalg
Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place : Mumbai
Date : 20/01/2025

Atul Shukla
(Company Secretary)
Membership Number : ACS46854
Place: Mumbai
Date : 20/01/2025



INFLUX HEALTHTECH LIMITED

(Formerly known as Influx Healthtech Private Limited)

SUMMARY STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES & NOTES TO RESTATED FINANCIAL INFORMATION

COMPANY OVERVIEW

Influx Healthtech Limited is a limited company incorporated on 28th September, 2020 under The Companies Act, 2013. The Company was converted From Private Limited Company to Public limited w.e.f. 23.05.2022. It has its registered office situated at 109, Ghanshyam Enclave Premises Co-op Society Plot no. 856, Laljipada, Kandivali West, Mumbai 400067. The company is engaged in the business of manufacturing and trading of Nutra Products and other related business activities.

The Company has its manufacturing unit at Plot no. 1,9,10 and 57, at Genesis Industrial Compound, Kolgaon, Palghar, Maharashtra - 401404

1 SIGNIFICANT ACCOUNTING POLICIES & NOTES TO ACCOUNTS

A Basis of Preparation of Financial statements

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis. These financial statements have been prepared to comply in all material aspects with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), specified under section 133 and other relevant provisions of the Companies Act, 2013.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non-current classification of assets and liabilities.

B Use of Estimates

The preparation of Financial Statements in conformity with Generally Accepted Accounting Principles in India requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the end of the reporting period. The estimates and assumptions used in the accompanying Financial Statements are based upon management's evaluation of the relevant facts and circumstances as of the date of the Financial Statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying Financial Statements. Any revisions to accounting estimates are recognized prospectively in current and future periods.

C Accounting Convention

The Company follows the mercantile system of accounting, recognizing income and expenditure on accrual basis. The accounts are prepared on historical cost basis and as a going concern.

Accounting policies not referred to specifically otherwise, are consistent with the generally accepted accounting principles.

The following significant accounting policies are adopted in the preparation and presentation of these financial statements:

D Current versus non-current classification

The assets and liabilities in the balance sheet are presented based on current and non-current classification:

An asset is current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle, or
- Held primarily for the purpose of trading, or
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when it is:

- Expected to be settled in normal operating cycle, or
- Held primarily for the purpose of trading, or
- Due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are treated as non-current. Deferred tax assets / liabilities are classified as non-current assets and liabilities respectively.

E Property, Plant & Equipment and Intangible Assets

(a) Tangible Assets

Property, Plant and Equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost comprises of the purchase price including import duties and non-refundable taxes, and directly attributable expenses incurred to bring the asset to the location and condition necessary for it to be capable of being operated in the manner intended by management. Subsequent costs related to an item of Property, Plant and Equipment are recognised in the carrying amount of the item if the recognition criteria are met.

Items of Property, Plant and Equipment that have been retired from active use and are held for disposal are stated at the lower of their net carrying amount and net realisable value and are shown separately in the financial statements under the head 'Other current assets'. Any write-down in this regard is recognised immediately in the Statement of Profit and Loss.

An item of Property, Plant and Equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising on derecognition is recognised in the Statement of Profit and Loss.

(b) Intangible Assets

(i) Acquired Intangible Assets

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Gains or losses arising from the retirement or disposal of an intangible asset are determined as the difference between the net disposal proceeds and the carrying amount of the asset and recognised as income or expense in the Statement of Profit and Loss.

(ii) Impairment of Assets

Assessment is done at each balance sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. For the purpose of assessing impairment, the recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. The smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit (CGU). An asset or CGU whose carrying value exceeds its recoverable amount is considered impaired and is written down to its recoverable amount. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased. An impairment loss is reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognised.

(c) Depreciation

Depreciation on tangible assets is provided to the extent depreciable amount on the Written Down Value(WDV) Method. Depreciation is provided based on useful life of assets as prescribed in Schedule II to the Companies Act, 2013.

Intangible assets are amortised on a straight line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

The estimates of useful lives of property plant and equipment are as follows :

Types Of Asset	Useful life as per Schedule II
Building	30
Plant and Machinery	15
Furniture and Fixtures	10
Office Equipment	5
Motor Vehicles	8
Computer Software	3 to 10

F Inventories

Inventories of Raw Materials are valued at lower of cost or net realizable value. The method used for valuation or determination of cost is as per First-in-First Out (FIFO) basis.

Inventories of stores, regular spares, fuel and packing material are valued at cost or net realizable value whichever is lower. First-in-First-Out (FIFO) method is used for valuation purpose. Inventories of finished goods are valued at lower of factory cost (including material, labour and related overheads and depreciation) and net realizable value.

Goods and Service Tax ('GST') Input, being tax which is set-off against GST output, does not form a part of cost of inventory as prescribed in AS – 2 on "Valuation of Inventories".

G Cash and Cash Equivalents

In the cash flow statement, cash and cash equivalents include cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

H Provisions and Contingent Liabilities

(a) Provisions

Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

(b) Contingent Liabilities

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

I Revenue Recognition

Sales are recognised when the significant risks and rewards of ownership in the goods are transferred to the buyer as per the terms of the contract, which coincides with the delivery of goods and are recognised net of trade discounts, rebates, Goods and Service tax.

Service income is accounted as and when services are rendered and are net of Goods and Service tax.

J Other Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the rate applicable.

Export benefits, incentives and licenses: Export incentives are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Rental income is recognised in the statement of profit and loss on the straight line basis over the period of lease term.

K Borrowing costs

Borrowing costs include interest, other costs incurred in connection with borrowing and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to the interest cost. General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognised in Statement of Profit and Loss in the period in which they are incurred.

L Employees Benefits

(a) Provident Fund

Contribution towards provident fund for employees is made to the regulatory authorities, where the Company has no further obligations. Such benefits are classified as Defined Contribution Schemes as the Company does not carry any further obligations, apart from the contributions made on a monthly basis.

(b) Gratuity

The Company provides for gratuity, a defined benefit plan (the "Gratuity Plan") covering eligible employees in accordance with the Payment of Gratuity Act, 1972. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/ gains are recognised in the Statement of Profit and Loss in the year in which they arise.

(c) Termination Benefits

Termination benefits in the nature of voluntary retirement benefits are recognised in the Statement of Profit and Loss as and when incurred.

M Current and Deferred Tax

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities.

Deferred tax is recognised for all the timing differences, subject to the consideration of prudence in respect of deferred tax assets. Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws.

N Foreign Currency Transaction

(a) Initial Recognition

On initial recognition, all foreign currency transactions are recorded by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

(b) Subsequent Recognition

As at the reporting date, non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. All non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

All monetary assets and liabilities in foreign currency are restated at the end of accounting period. With respect to long term foreign currency monetary items, the Company has adopted the following policy:

- Foreign exchange difference on account of a depreciable asset, is adjusted in the cost of the depreciable asset, which would be depreciated over the balance life of the asset

- In other cases, the foreign exchange difference is accumulated in a Foreign Currency Monetary Item Translation Difference Account, and amortised over the balance period of such long term asset/ liability

A monetary asset or liability is termed as a long-term foreign currency monetary item, if the asset or liability is expressed in a foreign currency and has a term of 12 months or more at the date of origination of the asset or liability.

Exchange differences on restatement of all other monetary items are recognised in the Statement of Profit and Loss.

O Earning / (loss) Per Share

Basic earnings / (loss) per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting preference dividends and any attributable tax thereto for the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	As at 30 November, 2024		As at 31 March, 2024		As at 31 March, 2023		As at 31 March, 2022	
		Number	Amount	Number	Amount	Number	Amount	Number	Amount
2	SHARE CAPITAL								
(a)	Authorised Capital								
	Equity Shares Of Rs. 10 Each	2,50,00,000	2,500.00	1,00,00,000	1,000.00	50,000	5.00	50,000	5.00
(b)	Issued, Subscribed & Fully Paid Up Capital								
	Equity Shares of Rs. 10 each fully Paid	1,81,50,000	1,815.00	25,000	2.50	25,000	2.50	25,000	2.50
			<u>1,815.00</u>		<u>2.50</u>		<u>2.50</u>		<u>2.50</u>

(c) **Par value per share:**

The Company has only one class of Equity Shares having a par value Rs. 10 per share.

(d) **A reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:**

Particulars	30 November, 2024		As at 31 March, 2024		As at 31 March, 2023		As at 31 March, 2022	
	No. of Shares	Amount	No. of Shares	Amount	No. of Shares	Amount	No. of Shares	Amount
Equity Shares at the beginning of the year	25,000	2,50,000	25,000	2,50,000	25,000	2,50,000	25,000	2,50,000
Add: Share issued during the year	1,81,25,000	18,12,50,000	-	-	-	-	-	-
Less: Shares bought back during the year	-	-	-	-	-	-	-	-
Equity Shares at the end of the year	1,81,50,000	18,15,00,000	25,000	2,50,000	25,000	2,50,000	25,000	2,50,000

(e) **The rights, preferences and restrictions attaching to each class of shares including restrictions on the distribution of dividends and the repayment of capital:**

The Company has issued only one class of equity shares having a par value of Rs. 10 each. Each equity shareholder is entitled to one vote per share. Dividend, if any, is declared and paid in Indian Rupees. Dividend, if any, proposed by the Board of Director is subject to the approval of the share holders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be proportion to the number of equity shares held by the shareholders.

(f) **Shares in respect of each class in the company held by its holding company or its ultimate holding company including shares held by or by subsidiaries or associates of the holding company or the ultimate holding company in aggregate:**

There are no holding, subsidiary or associate companies. Accordingly reporting to that extent under this clause is not applicable.

(g) Shares in the company held by each shareholder holding more than 5 per cent. shares specifying the number of shares held:

Name of Shareholders	30 November, 2024		As at 31 March, 2024		As at 31 March, 2023		As at 31 March, 2022	
	No. of Shares	% Held	No. of Shares	% Held	No. of Shares	% Held	No. of Shares	% Held
Munir Chandniwala	1,72,42,500	95.00%	23,750	95.00%	23,750	95.00%	23,750	95.00%
Shirin Chandniwala							1,250	5.00%

(h) Aggregate number of bonus shares issued or shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting date.

Particulars	As at 30.11.2024		As at 31.03.2024		As at 31.03.2023		As at 31.03.2022	
	(No. of Shares)	(No. of Shares)	(No. of Shares)	(No. of Shares)	(No. of Shares)	(No. of Shares)	(No. of Shares)	(No. of Shares)
Equity shares allotted as fully paid up pursuant to contracts for consideration other than cash		Nil	Nil	Nil	Nil	Nil	Nil	Nil
a) Subscription amount is adjusted against a bona fide debt payable in money at once by the company.		Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Conversion of loan into shares in the event of default in repayment.		Nil	Nil	Nil	Nil	Nil	Nil	Nil
b) Conversion of loan into shares in the event of default in repayment.		Nil	Nil	Nil	Nil	Nil	Nil	Nil
d) Equity Shares allotted as fully paid bonus shares by capitalisation of reserves		1,81,25,000	Nil	Nil	Nil	Nil	Nil	Nil

(i) Shareholding of Promoters

The details of the shares held by promoters as at November 30, 2024 are as follows :

Promoter Name	No. of Shares	% of Total Shares	% change during the year
Munir Chandniwala	1,72,42,500	95.00%	0.00%
Shirin Chandniwala	8,80,638	4.85%	-0.13%
Abdul Chandniwala	726	0.00%	0.00%
Total	1,81,23,864	99.86%	

The details of the shares held by promoters as at March 31, 2024 are as follows :

Promoter Name	No. of Shares	% of Total Shares	% change during the year
Munir Chandniwala	23,750	95.00%	0.00%
Shirin Chandniwala	1,245	4.98%	0.00%
Abdul Chandniwala	1	0.00%	0.00%
Total	24,996	99.98%	

The details of the shares held by promoters as at March 31, 2023 are as follows :

Promoter Name	No. of Shares	% of Total Shares	% change during the year
Munir Chandniwala	23,750	95.00%	0.00%
Shirin Chandniwala	1,245	4.98%	-0.02%
Abdul Chandniwala	1	0.00%	100.00%
Total	24,996	99.98%	

The details of the shares held by promoters as at March 31, 2022 are as follows :

Promoter Name	No. of Shares	% of Total Shares
Munir Chandniwala	23,750	95.00%
Shirin Chandniwala	1,250	5.00%
Total	25,000	100.00%

Note No.	Particulars	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
3	RESTATED RESERVES & SURPLUS				
	Reserves and Surplus Consists of following reserves :				
	General Reserve				
	Opening Balance	650.00	650.00	-	-
	Add: Transferred from Profit / Loss account	-	-	650.00	-
	Less: Transferred on account of bonus issue of shares	(650.00)	-	-	-
	Total(A)	-	650.00	650.00	-
	Profit & Loss Account				
	Opening Balance	1,634.72	512.65	443.01	(0.44)
	Add: Profit/(Loss) for the year	804.50	1,122.08	719.63	443.45
	Less: Transfer to general reserve	-	-	(650.00)	-
	Less: Transferred on account of bonus issue of shares	(1,162.50)	-	-	-
	Total(B)	1,276.72	1,634.72	512.65	443.01
	Total(A+B)	1,276.72	2,284.72	1,162.65	443.01
4	RESTATED LONG-TERM BORROWINGS				
	Secured				
	Term Loan from Bank	-	-	3.29	7.85
	Total	-	-	3.29	7.85
	Terms of Repayment & other disclosures				
	A) Term Loan from Bank is secured by hypothecation of vehicle				
	B) The rate of interest on the above term loan is 9.47%				
	C) The aforesaid term loan is repayable in 36 equal monthly instalments of Rs. 42,586 commencing from 5th December 2021. Further, the company has foreclosed the term loan in FY 2024-2025.				
	Repayment Schedule				
	Financial Year	2024-25	2023-24	2022-23	2021-22
	F.Y. 2024-25	-	3.29	3.29	3.29
	F.Y. 2023-24	-	-	4.56	4.56
	F.Y. 2022-23	-	-	-	4.15
5	RESTATED DEFERRED TAX LIABILITIES (NET)				
	Deferred Tax liability				
	Depreciation	-	-	1.39	2.80
	Total	-	-	1.39	2.80
6	RESTATED OTHER LONG TERM LIABILITIES				
	Security Deposits				
	From Customer	5.26	5.26	5.26	-
	Total	5.26	5.26	5.26	-
7	RESTATED LONG TERM PROVISION				
	Provision for Gratuity	-	28.66	16.27	6.81
	Total	-	28.66	16.27	6.81
8	RESTATED SHORT TERM BORROWINGS				
	Unsecured*				
	Repayable on demand - Interest Free				
	From Directors				
	Munir Chandniwala	24.74	27.19	65.00	42.00
	Shirin Munir Chandniwala	2.00	2.00	7.00	7.00
	Total	26.74	29.19	72.00	49.00

Note No.	Particulars	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
9	RESTATED TRADE PAYABLES				
	(a) Total outstanding dues of micro enterprises and small enterprises*	688.93	387.07	221.66	113.81
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,496.54	1,049.47	1,123.82	989.67
	Total	2,185.47	1,436.54	1,345.48	1,103.47

* The information regarding Micro and Small enterprises have been determined to the extent such parties have been identified on the basis of information available with the Company.

(a) Trade payable ageing schedule

Figures for Reporting Period ended 30 November, 2024

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues- MSME	3.34	684.62	0.98	-	-	688.93
Undisputed Dues-Other than MSME	37.22	1,450.52	8.81	-	-	1,496.54
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues- Others	-	-	-	-	-	-
Total	40.55	2,135.13	9.79	-	-	2,185.47

Figures for Reporting period - FY 2023-24

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues- MSME	2.25	384.82	-	-	-	387.07
Undisputed Dues-Other than MSME	13.09	1,016.25	20.13	-	-	1,049.47
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues- Others	-	-	-	-	-	-
Total	15.34	1,401.08	20.13	-	-	1,436.54

Figures for Reporting Period-FY 2022-23

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues- MSME	-	221.66	-	-	-	221.66
Undisputed Dues-Other than MSME	13.30	1,110.38	0.15	-	-	1,123.82
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues- Others	-	-	-	-	-	-
Total	13.30	1,332.03	0.15	-	-	1,345.48

Figures for Reporting Period-FY 2021-22

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues-MSME	-	113.81	-	-	-	113.81
Undisputed Dues- Other than MSME	-	989.67	-	-	-	989.67
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues- Others	-	-	-	-	-	-
Total	-	1,103.47	-	-	-	1,103.47

(Formerly known as Influx Healthtech Private Limited)

Notes forming part of Restated Financial Statements

(b) Dues to Micro and Small Enterprises

The disclosure pursuant to the said Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act') are as follows: -

Particulars	As at November 30, 2024	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Principal amount due to suppliers registered under the MSMED Act and	685.59	384.82	221.66	113.81
Interest due thereon to suppliers registered under the MSMED Act and	-	-	-	-
Principal amounts paid to suppliers registered under the MSMED Act, beyond	-	-	-	-
Interest paid under Section 16 of MSMED Act to suppliers registered under the	-	-	-	-
Amount of interest due and payable for the period (where the principal has	-	-	-	-
Interest accrued and remaining unpaid at the end of each accounting year	-	-	-	-

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

Note No.	Particulars	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
10	RESTATED OTHER CURRENT LIABILITIES				
	Secured				
	Current Maturities of Long Term Borrowings*	-	3.29	4.56	4.15
	Statutory dues Payable	31.34	17.43	18.21	12.22
	Advance Received from Customers	158.77	102.04	110.15	55.52
	Employee Dues Payable	66.86	49.29	59.58	44.54
	Interest Accrued but not Due	-	-	0.05	0.08
	<i>* Security details are mentioned in Note 4</i>				
	Total	256.96	172.05	192.55	116.51
11	RESTATED SHORT TERM PROVISIONS				
	Provision for Tax (Net of advances)	130.34	151.38	29.03	26.87
	Total	130.34	151.38	29.03	26.87

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

12 Property, Plant and Equipment

(All Amounts in Rs. Lakhs, unless otherwise stated)

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK			D E P R E C I A T I O N			NET BLOCK		
		AS AT 01/04/2024	ADDITION DURING THE YEAR	DEDUCTION DURING THE YEAR	AS AT 30/11/2024	UP TO 31/03/2024	ADDITION DURING THE YEAR	DEDUCTIONS DURING THE YEAR	AS AT 30/11/2024	AS AT 30/11/2024
a)	TANGIBLE ASSETS									
	Premises	406.54	224.90	-	631.43	29.60	30.26	-	59.86	571.58
	<i>(the above asset is Capital cost on Rented Property)</i>									
	Plant & Machinery	1,080.01	146.14	-	1,226.15	207.96	112.84	-	320.79	905.36
	Office Equipment	29.19	9.94	-	39.13	15.16	4.53	-	19.69	19.43
	Furniture & Fixtures	117.21	36.62	-	153.83	23.16	18.72	-	41.87	111.96
	Motor Vehicle	18.87	0.79	-	19.66	9.05	2.14	-	11.19	8.47
	Computer Hardware	8.85	1.55	-	10.40	5.15	2.07	-	7.21	3.18
		1,660.67	419.93	-	2,080.60	290.08	170.54	-	460.62	1,619.98
b)	INTANGIBLE ASSETS									
	Computer Software	3.68	-	-	3.68	1.29	0.41	-	1.71	1.97
		3.68	-	-	3.68	1.29	0.41	-	1.71	1.97
	Total	1,664.35	419.93	-	2,084.28	291.37	170.96	-	462.33	1,621.95

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

12 Property, Plant and Equipment

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK				DEPRECIATION				NET BLOCK		
		AS AT 01/04/2023	ADDITION DURING THE YEAR	DEDUCTION DURING THE YEAR	AS AT 31/03/2024	UP TO 31/03/2023	ADDITION DURING THE YEAR	DEDUCTIONS DURING THE YEAR	AS AT 31/03/2024	AS AT 31/03/2024	AS AT 31/03/2024	
a)	TANGIBLE ASSETS											
	Premises	121.39	285.15	-	406.54	6.08	23.52	-	29.60	376.93		
	<i>(the above asset is Capital cost on Rented Property)</i>											
	Plant & Machinery	524.89	555.12	-	1,080.01	77.95	130.01	-	207.96	872.06		
	Office Equipment	22.42	6.77	-	29.19	5.84	9.33	-	15.16	14.02		
	Furniture & Fixtures	43.92	73.28	-	117.21	8.82	14.33	-	23.16	94.05		
	Motor Vehicle	16.17	2.70	-	18.87	5.66	3.39	-	9.05	9.83		
	Computer Hardware	6.31	2.54	-	8.85	1.13	4.02	-	5.15	3.70		
		735.11	925.56	-	1,660.67	105.47	184.60	-	290.08	1,370.60		
b)	INTANGIBLE ASSETS											
	Computer Software	3.68	-	-	3.68	0.46	0.83	-	1.29	2.39		
		3.68	-	-	3.68	0.46	0.83	-	1.29	2.39		
	Total	738.79	925.56	-	1,664.35	105.94	185.43	-	291.37	1,372.98		

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

12 Property, Plant and Equipment

(All Amounts in Rs. Lakhs, unless otherwise stated)

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK			D E P R E C I A T I O N			NET BLOCK		
		AS AT 01/04/2022	ADDITION DURING THE YEAR	DEDUCTION DURING THE YEAR	AS AT 31/03/2023	UP TO 31/03/2022	ADDITION DURING THE YEAR	DEDUCTIONS DURING THE YEAR	AS AT 31/03/2023	AS AT 31/03/2023
a)	TANGIBLE ASSETS									
	Premises	13.07	108.31	-	121.39	0.11	5.97	-	6.08	115.31
	<i>(the above asset is Capital cost on Rented Property)</i>									
	Plant & Machinery	238.77	286.12	-	524.89	8.96	68.99	-	77.95	446.95
	Office Equipment	5.86	16.56	-	22.42	1.15	4.69	-	5.84	16.58
	Furniture & Fixtures	15.77	28.16	-	43.92	0.19	8.64	-	8.82	35.10
	Motor Vehicle	11.64	4.53	-	16.17	1.55	4.10	-	5.66	10.52
	Computer Hardware	1.20	5.11	-	6.31	0.25	0.88	-	1.13	5.18
		286.31	448.80	-	735.11	12.20	93.28	-	105.47	629.64
b)	INTANGIBLE ASSETS									
	Computer & Software	-	3.68	-	3.68	-	0.46	-	0.46	3.22
		-	3.68	-	3.68	-	0.46	-	0.46	3.22
	Total	286.31	452.48	-	738.79	12.20	93.74	-	105.94	632.85

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

12 Property, Plant and Equipment

(All Amounts in Rs. Lakhs, unless otherwise stated)

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK			D E P R E C I A T I O N			NET BLOCK		
		AS AT 01/04/2021	ADDITION DURING THE YEAR	DEDUCTION DURING THE YEAR	AS AT 31/03/2022	UP TO 31/03/2021	ADDITION DURING THE YEAR	DEDUCTIONS DURING THE YEAR	AS AT 31/03/2022	AS AT 31/03/2022
a)	TANGIBLE ASSETS									
	Premises	-	13.07	-	13.07	-	0.11	-	0.11	12.96
	<i>(the above asset is Capital cost on Rented Property)</i>									
	Plant & Machinery	-	244.24	5.47	238.77	-	8.96	-	8.96	229.82
	Office Equipment	-	5.86	-	5.86	-	1.15	-	1.15	4.71
	Furniture & Fixtures	-	15.77	-	15.77	-	0.19	-	0.19	15.58
	Motor Vehicle	-	11.64	-	11.64	-	1.55	-	1.55	10.09
	Computer Hardware	-	1.20	-	1.20	-	0.25	-	0.25	0.95
		-	291.78	5.47	286.31	-	12.20	-	12.20	274.11
b)	INTANGIBLE ASSETS									
	Computer & Software	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-
	Total	-	291.78	5.47	286.31	-	12.20	-	12.20	274.11

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

Note No.	Particulars	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
13	RESTATED DEFERRED TAX ASSET (NET)				
	Deferred Tax Asset				
	- On account of disallowance u/s 43B	-	28.61	-	-
	- On account of Depreciation	4.96	-	-	-
	Deferred Tax Liabilities				
	- On account of Depreciation	-	(0.04)	-	-
	Total	4.96	28.56	-	-
14	RESTATED LONG TERM LOANS AND ADVANCES				
	Unsecured & Considered Good				
	Rental Deposits	118.49	117.08	115.03	55.03
	Capital Advances	102.86	23.40	76.11	47.30
	Deposit with others	0.23	0.10	0.10	-
	Total	221.58	140.58	191.24	102.33
	<i>(a) Loans and Advances due by directors or other officers of the company</i>	136.00	115.00	115.00	55.00
	<i>(b) Loans and Advances due by firm or private companies in which director is a partner or director or member</i>	Nil	Nil	Nil	Nil
	<i>(c) Loans or advances in the nature of loans granted to Promoters, Directors, Krmps and their related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:</i>				
	<i>(i) repayable on demand; or</i>	Nil	Nil	Nil	Nil
	<i>(ii) without specifying any terms or period of repayment</i>	Nil	Nil	Nil	Nil
	<i>(d) In line with Circular No. 04/2015 issued by the Ministry of Corporate Affairs dated March 10, 2015, loans given to employees as per the Company's policy are not considered for the purpose of disclosure under section 186(4) of the Companies Act, 2013.</i>				
15	Other non current assets				
	Gratuity Asset	0.44	-	-	-
	Total	0.44	-	-	-
16	RESTATED INVENTORIES				
	Raw Materials	402.60	307.82	78.85	71.20
	Packing Materials	178.84	158.95	75.49	64.86
	Finished Goods	83.89	78.85	41.85	39.43
	Total	665.33	545.62	196.19	175.49
17	RESTATED TRADE RECEIVABLES				
	Secured, Considered Good	5.26	5.26	5.26	-
	Unsecured, Considered Good	2,591.50	1,586.34	1,377.25	1,031.06
	Doubtful	50.52	18.53	-	-
	Less: Allowance for Bad and Doubtful Debts	-	(18.53)	-	-
	Total	2,647.28	1,591.60	1,382.51	1,031.06
	<i>Debts Due by firm or private companies in which director is partner, director or member</i>	7.39	4.85	0.16	Nil
	<i>Debts Due by directors or other officers of the company</i>	Nil	Nil	Nil	Nil

Figures for Reporting Period ended 30 November,2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	2,416.10	180.66	-	-	-	2,596.76
considered doubtful	-	-	50.52	-	-	50.52
Disputed Trade Receivables						
considered good	-	-	-	-	-	-
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts	-	-	-	-	-	-
Total	2,416.10	180.66	50.52	-	-	2,647.28

Figures for Reporting Period-FY 2023-24

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	1,496.28	95.32	-	-	-	1,591.60
considered doubtful	-	-	18.53	-	-	18.53
Disputed Trade Receivables						
considered good	-	-	-	-	-	-
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts	-	-	(18.53)	-	-	(18.53)
Total	1,496.28	95.32	-	-	-	1,591.60

Figures for Reporting Period-FY 2022-23

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	9.88	1,372.62	-	-	-	1,382.51
considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables						
considered good	-	-	-	-	-	-
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts	-	-	-	-	-	-
Total	9.88	1,372.62	-	-	-	1,382.51

Figures for Reporting Period-FY 2021-22

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	1,016.03	15.03	-	-	-	1,031.06
considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables						
considered good	-	-	-	-	-	-
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts	-	-	-	-	-	-
Total	1,016.03	15.03	-	-	-	1,031.06

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

Note No.	Particulars	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
18	RESTATED CASH AND BANK BALANCES				
	Balances with banks				
	In Current Account	266.45	288.16	353.28	145.34
	Cash and Cash equivalents				
	Cash on Hand	3.54	2.41	1.42	1.19
	Other Bank Balances				
	Deposits with maturity more than 3 months but less than 12 months	70.00	70.00	-	-
	Total	340.00	360.56	354.71	146.52
19	RESTATED SHORT TERM LOANS AND ADVANCES				
	(Unsecured-Considered Good)				
	Advance paid against supply of goods & services	98.55	28.07	38.29	8.08
	Loans and advances to Employees	18.61	18.48	17.53	10.74
	Prepaid Expenses	21.23	4.52	2.77	-
	Input tax credit available for utilisation	-	17.24	14.34	10.49
	Total	138.39	68.31	72.93	29.31
	<i>Loans and Advances due by directors or other officers of the company</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
	<i>Loans and Advances due by firm or private companies in which director is a partner or director or member</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
	<i>Loans or advances in the nature of loans granted to Promoters, Directors, KMPs and their related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:</i>				
	<i>(i) repayable on demand; or</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
	<i>(ii) without specifying any terms or period of repayment</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
	<i>In line with Circular No. 04/2015 issued by the Ministry of Corporate Affairs dated March 10, 2015, loans given to employees as per the Company's policy are not considered for the purpose of disclosure under section 186(4) of the Companies Act, 2013.</i>				
20	RESTATED OTHER CURRENT ASSETS				
	Deferred Share Issue expenses	48.55	-	-	-
	Interest receivable on fixed deposits	5.63	2.09	-	-
	Rent receivable	2.40	-	-	-
	Total	56.58	2.09	-	-
21	RESTATED CONTINGENT LIABILITIES				
	Contingent Liabilities as at the reporting date	Nil	Nil	Nil	Nil

(Formerly known as Influx Healthtech Private Limited)

Notes forming part of Restated Financial Statements

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the period ended	For the period ended	For the year ended	For the year ended
		30 November, 2024	31 March, 2024	31 March, 2023	31 March, 2022
22	RESTATED REVENUE FROM OPERATION				
	Sale of products	6,234.99	9,913.24	7,503.25	5,892.00
	Other Operating revenues	39.93	83.77	102.41	78.17
	Total	6,274.92	9,996.51	7,605.65	5,920.17
23	RESTATED OTHER INCOME				
	Balance written back	28.55	8.64	1.10	-
	Rent Received	2.40	2.70	-	-
	Interest received on Fixed Deposit	3.78	2.32	-	-
	Gain on variation in foreign exchange rate	-	0.07	-	-
	Reversal of provision for doubtful debts	18.52	-	-	-
	Duty Drawback Income Received	0.06	-	-	-
	Actuarial Gains on gratuity fund	0.44	-	-	-
	Total	53.75	13.73	1.10	-
24	RESTATED COST OF MATERIAL CONSUMED				
	Opening Stock				
	Raw Material	307.82	78.85	71.20	-
	Packing Material	158.95	75.49	64.86	-
		466.77	154.34	136.06	-
	Add: Purchases				
	Raw Material	2,775.83	5,087.87	3,999.90	3,648.57
	Packing Material	1,166.34	1,751.50	1,292.63	1,079.75
		3,942.18	6,839.37	5,292.53	4,728.32
	Less: Closing Stock				
	Raw Material	(402.60)	(307.82)	(78.85)	(71.20)
	Packing Material	(178.84)	(158.95)	(75.49)	(64.86)
		(581.45)	(466.77)	(154.34)	(136.06)
	Total	3,827.50	6,526.94	5,274.25	4,592.26
25	RESTATED CHANGES IN INVENTORIES OF FINISHED GOODS				
	Opening Stock of Goods				
	Finished Goods	78.85	41.85	39.43	-
	Total (I)	78.85	41.85	39.43	-
	Closing Stock of Goods				
	Finished Goods	83.89	78.85	41.85	39.43
	Total (II)	83.89	78.85	41.85	39.43
	Net Impact (I-II)	(5.03)	(37.01)	(2.42)	(39.43)
26	RESTATED EMPLOYEE BENEFIT EXPENSES				
	Salaries, Wages & Allowances	438.49	571.09	411.99	278.72
	Directors Remuneration	60.00	60.00	33.00	20.00
	Director Commission	-	-	20.00	12.00
	Contribution to Provident fund and other fund	26.36	38.80	30.27	21.09
	Group Insurance for Staff	2.06	1.72	1.18	2.20
	Staff Welfare Expenses	11.95	20.20	9.52	5.73
	Gratuity Premium	-	12.39	9.46	6.81
	Total	538.85	704.20	515.42	346.55
27	RESTATED FINANCE COSTS				
	Interest Expenses				
	Secured Loan	0.09	0.50	0.93	0.49
	Interest on statutory dues	0.21	0.13	0.03	0.03
	Other borrowing costs				
	Bank Charges	0.14	0.46	1.02	2.38
	Bill Discount Charges	-	4.80	4.01	1.29
	Total	0.44	5.89	5.99	4.185

(Formerly known as Influx Healthtech Private Limited)

Notes forming part of Restated Financial Statements

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the period ended 30 November, 2024	For the period ended 31 March, 2024	For the year ended 31 March, 2023	For the year ended 31 March, 2022
28	RESTATED OTHER EXPENSES				
	Manufacturing Expenses				
	Cartridge Filling Expenses	10.00	18.36	19.29	9.12
	Factory Expenses	40.53	64.19	38.90	28.75
	Factory Rent	56.65	84.00	68.52	-
	Grampanchayat Tax	-	-	1.81	-
	Laboratory Expenses	10.55	6.71	1.85	0.06
	Labour Charges	243.62	319.26	225.97	145.61
	Power & Fuel Charges	76.34	96.06	64.59	38.12
	Packing & Forwarding	5.86	15.94	11.70	1.00
	Transportation Expenses	57.28	96.33	61.96	27.43
	Other Production Expenses	-	3.07	3.93	2.78
		500.83	703.91	498.50	252.88
	Administrative & Other Expenses				
	<u>Auditor's Remuneration</u>				
	Audit Fees	1.67	2.50	2.00	2.00
	Tax Audit Fees	-	-	0.50	0.50
	Advertisement Expense	0.54	0.30	2.62	-
	Bad Debts	-	13.20	2.64	-
	Provision for Doubtful Debts (net of reversal)	-	18.53	-	-
	Computer & Internet Expenses	1.11	2.37	0.86	-
	Courier Charges	5.04	5.80	4.56	2.01
	Corporate Social Responsibility Expenses	1.20	11.46	6.75	-
	Donation	1.52	5.44	2.13	1.09
	Electricity Expenses	2.40	3.14	2.48	4.60
	GST Payment	-	0.29	0.25	-
	Insurance Expenses	1.24	4.32	0.57	2.30
	License & Registration Fees	1.04	6.74	4.90	2.24
	Legal & Professional Fees	49.53	60.67	17.71	5.30
	Membership & Subscription Fees	0.71	0.62	0.43	1.23
	Mobile & Telephone charges	1.04	1.33	0.45	0.35
	Office Expenses	0.90	0.36	3.43	2.91
	Office Rent	22.58	31.88	18.00	50.02
	Professional Tax - Company	-	0.03	0.03	0.03
	Printing & Stationery	2.05	2.48	7.72	2.23
	Repair & Maintenance	25.67	70.13	14.47	10.92
	Security Charges	-	0.68	9.35	6.86
	Software Expenses	2.12	3.30	0.29	1.70
	Society Maintenance Charges	1.88	2.81	2.78	2.77
	Vehicle Expenses	7.07	9.22	2.55	-
	Travelling & Conveyance Expenses	18.53	33.64	22.59	17.10
	Loss of Sale of Assets	-	-	-	0.37
	Loss on variation in foreign exchange rate	0.41	-	-	-
	Sundry Balance written off	-	-	-	0.02
		148.23	291.25	130.08	116.54
	Selling & Marketing Expenses				
	Commission	22.26	42.65	34.25	19.44
	Digital Marketing Expenses	-	-	5.10	-
	Exhibition Expenses	50.30	71.35	65.38	13.56
	Sales Promotion Expenses	1.82	1.73	4.82	1.40
	Website Expenses	3.14	4.11	8.02	-
		77.53	119.84	117.56	34.40
	Total	726.59	1,115.00	746.14	403.81

(Formerly known as Influx Healthtech Private Limited)

Notes forming part of Restated Financial Statements

29 Disclosures as required by AS 18 "Related Parties" issued by the ICAI

List of Related Parties

Sr.No	Name of Related Party	Relationship
1	Munir Chandniwala	Managing Director
2	Shirin Chandniwala	Whole Time Director
3	Abdul Ganee Chandniwala	Director
4	Ashish Shah	Chief Financial Officer (appointed on 2nd May 2024)
5	Atul Shukla	Company Secretary (appointed on 2nd May 2024)
6	ESLP Digital LLP	Group Entity
7	Influx Healthcare	Group Entity
8	Trusan Printpack Private Limited	Group Entity
9	Chandniwala Clinic	Group Entity
10	Influx Foundation	Group Entity
11	Nutrapharm India	Group Entity
12	Shinaf Enterprise	Group Entity

Summary of significant related party transactions carried out in the ordinary course of business are as under :

(Rs. in lakhs, unless otherwise stated)

Sl.	Nature of Transaction	Period Ended 30 November,2024	Year Ended 31 March,2024	Year Ended 31 March,2023	Year Ended 31 March,2022
I	Key Management Personnel				
(i)	Munir Chandniwala				
	Remuneration	52.00	60.00	33.00	20.00
	Commission	-	-	20.00	12.00
	Loan taken	11.59	44.70	23.00	55.00
	Loan Repaid	14.04	82.51	-	13.00
	Rent Paid	60.00	90.00	69.00	37.50
	Advance for Plot No. 59	9.90	-	-	-
	Advance for Plot No. 28	10.89	-	-	-
(ii)	Shirin Chandniwala				
	Remuneration	8.00	-	-	-
	Loan Taken	-	-	-	7.00
	Loan Repaid	-	5.00	-	-
	Rent Paid	8.00	12.00	12.00	10.00
(iii)	Ashish Shah				
	Remuneration	6.43	8.99	5.97	5.86
(iv)	Atul Shukla				
	Remuneration	1.40	-	-	-
II	Other Related Party				
(i)	Trusan Printpack Private Limited				
	Sale of product	0.51	2.52	-	-
	Purchase of product	133.24	38.48	-	-
	Rent Income	2.40	2.70	-	-
(ii)	Influx Healthcare				
	Purchase of product	-	-	289.75	430.88
	Purchase of Fixed asset	-	-	108.43	183.30
	Sales of product	-	-	4.21	-
	License & Registration Fees	-	6.74	-	-
(iii)	Influx Foundation				
	Donation	0.35	-	-	-
(iv)	Nutrapharm India				
	Sale of product	0.02	4.69	0.16	-
(v)	Shinaf Enterprises				
	Packing material purchase	-	-	-	90.08
	Other operating revenue	-	-	-	1.34

**INFLUX HEALTHTECH LIMITED**

(Formerly known as Influx Healthtech Private Limited)

Notes forming part of Restated Financial Statements**Balance at the Year End**

(Rs. in lakhs, unless otherwise stated)

Sr.No	Name	Nature of Transaction	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
1	Munir Chandniwala	Remuneration	5.81	1.30	-	1.15
2	Munir Chandniwala	Commission	-	-	-	12.00
3	Munir Chandniwala	Unsecured Loan	24.74	27.19	65.00	42.00
4	Munir Chandniwala	Security Deposit	115.00	115.00	115.00	55.00
5	Munir Chandniwala	Other receivables	-	-	0.002	-
6	Munir Chandniwala & Shirin Chandniwala	Advance for Plot No. 59	11.00	-	-	-
7	Munir Chandniwala & Shirin Chandniwala	Advance for Plot No. 28	10.00	-	-	-
8	Munir Chandniwala	Rent Payable	2.75	-	-	-
9	Shirin Chandniwala	Remuneration	6.00	-	-	-
10	Shirin Chandniwala	Unsecured Loan	2.00	2.00	7.00	7.00
11	Influx Healthcare	Purchase of product	-	-	52.64	0.05
12	Trusan Printpack Private Limited	Purchase of product	48.84	1.63	-	-
13	Trusan Printpack Private Limited	Rent receivable	2.40	-	-	-
14	Nutrpharm India	Sale of product	4.99	4.85	0.16	-
15	Shinaf Enterprises	Packing material purchase	-	-	11.87	14.03

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

**30 Disclosure as required by AS 20 "Earnings Per Share" issued by the ICAI
Earning Per Share (EPS)**

The earning considered in ascertaining the Company's EPS comprises the net profit after tax the number of shares used in Computation of Basic EPS is the weighted average number of share outstanding during the year which is calculated as below:

(Rs. in lakhs, unless otherwise stated)

Particular	For the Period Ended November, 2024	For the Year Ended March, 2024	For the Year Ended March, 2023	For the Year Ended March, 2022
Calculation of weighted average no. equity shares :				
No. of Shares at the beginning of the year fully paid	25,000	25,000	25,000	25,000
No. of Shares to issued fully paid	1,81,25,000	Nil	Nil	Nil
Total Equity Shares outstanding at the end of the year/period	1,81,50,000	25,000	25,000	25,000
Total Equity Shares outstanding at the end of the year/period (considering the impact of bonus issue for all periods)	1,81,50,000	1,81,50,000	1,81,50,000	1,81,50,000
Net Profit after tax / (loss) available for equity share holder (Rs. in Lakhs)	804.50	1,172.08	719.63	443.45
Basic / Diluted earnings per share of Rs. 10 (Rs.) (without considering the impact of bonus issue for all periods)	4.43	4,488.31	2,878.54	1,773.81
Basic / Diluted earnings per share of Rs. 10 (Rs.) (considering the impact of bonus issue for all periods)	4.43	6.18	3.96	2.44

Note : The EPS for the period ended 30th November 2024 is not annualised

31 Disclosure related to Corporate Social Responsibility (as per Section 135 of the Act)

(Rs. in lakhs, unless otherwise stated)

Particulars	For the Period Ended November 30, 2024	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023	For the Year Ended March 31, 2022
(a) Gross amount required to be spent by the Company during the year	15.23	10.60	6.07	-
(b) Amount of expenditure incurred on :				
(i) Construction/Acquisition of asset	-	-	-	-
(ii) On purposes other than (i) above	1.20	11.46	6.75	-
(c) Shortfall at the end of the year	N.A	N.A	N.A	N.A
(d) Total amount of previous years shortfall	N.A	N.A	N.A	N.A
(e) Reason for shortfall	N.A	N.A	N.A	N.A
(f) Contribution to a trust controlled by the company in relation to CSR Expenditure	N.A	N.A	N.A	N.A
(g) Where a provision is made with respect to a liability incurred by entering into a contractual obligation	N.A	N.A	N.A	N.A

The Company undertakes the following activities in Corporate social responsibility (CSR):

- (i) Promoting of education, including special education and employment enhancing vocation skills especially among children, women, elderly, and the differently abled and livelihood enhancement projects.
- (ii) eradicating hunger, poverty and malnutrition, promoting health care including preventive health and sanitation Including contribution to the Swatch Bharat Kosh set-up by the Central Government for the promotion of sanitation and making available safe drinking water.



INFLUX HEALTHTECH LIMITED

(Formerly known as Influx Healthtech Private Limited)

Notes forming part of Restated Financial Statements

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the period ended November 30, 2024	For the period ended March 31, 2024	For the period ended March 31, 2023	For the period ended March 31, 2022
32	Employee Benefit Expenses				
	(a) Defined Contribution Plans				
	Amount recognised in the Statement of Profit and Loss				
(i)	Employers' Contribution to Provident Fund * [Includes Employers' Contribution to Employee's Pension Scheme 1995]	20.74	30.26	23.29	15.81
(ii)	Employers' Contribution to Employee's State Insurance Commission*	5.57	8.50	6.88	5.19
		26.32	38.75	30.17	21.00

* Included in Contribution to Provident and Other Funds(Refer Note 24)

(b) Defined Benefit Plan

Gratuity

The Company has adopted the Accounting Standard 15 (revised 2005) on Employee Benefits during the restated financials period. The disclosure as envisaged under the Accounting Standard is provided here under:

Reconciliation of net defined benefit liability

Net opening provision in the books	28.66	16.27	6.81	-
Employees Benefit Expenses	(0.44)	12.39	9.46	6.81
Benefits paid by the Company	-	-	-	-
Contribution to planned asset	(28.66)	-	-	-
Closing provision	(0.44)	28.66	16.27	6.81

Bifurcation of Liability

Non- current Asset	0.44	-	-	-
Current Liability	-	0.31	0.03	0.06
Non- current liability	-	28.35	16.24	6.75
Net Liability	0.44	28.66	16.27	6.81

Principal actuarial assumptions

Discount Rate per annum	6.85%	6.97%	7.21%	7.30%
Salary escalation rate	7.00%	7.00%	7.00%	7.00%

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

33 Impairment of Assets

There is no such impairable asset for the period as ended on 30.11.2024 in terms of AS-28. Hence company has not made any provision for impairment loss.

34 Segment Reporting

The company is engaged in multiple business segment but there are no multiple reportable segments as defined in Accounting standard – 17 “Segment Reporting”.

35 Foreign Exchange transactions :

(Rs. in lakhs, unless otherwise stated)

Particular	For the Period Ended November, 2024	For the Year Ended March, 2024	For the Year Ended March, 2023	For the Year Ended March, 2022
Export of goods on F.O.B Basis	45.62	25.58	2.45	1.90
CIF Value of Import	-	-	-	-
Remittance of Dividend in Foreign Currency	-	-	-	-
Expenditure in Foreign Currency	-	-	-	-

36 Disclosure of transactions with struck off companies :

The Company did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.

37 Registration of Charges or Satisfaction with Registrar of Companies(ROC)

There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.

38 Compliance with number of layers of Companies

The Company has complied with the requirements of the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with Companies (Restriction on number of Layers) Rules, 2017.

39 Disclosure in relation to undisclosed income

During the year, the Company has not surrendered or disclosed any income in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961). Accordingly, there are no transactions which are not recorded in the books of accounts.

40 Financial Ratio

Sr. no.	Particulars	Numerator	Denominator	November 30,2024	March 31,2024	March 31,2023	March 31,2022	Variance for financial year ended March 31,2024	Variance for financial year ended March 31,2023
I	Current Ratio (in times)	Total Current Asset	Total Current Liabilities	1.48	1.44	1.22	1.07	17.26%	14.74%
II	Debt - Equity Ratio (in times)	Total Debt	Shareholders' Equity	0.01	0.01	0.06	0.13	-80.23%	-49.36%
III	Debt - Service Coverage Ratio (in times)	Earnings available for debt service	Debt Service	38.79	51.20	12.77	10.49	300.87%	21.76%
IV	Return on equity ratio (in %)	Net Profits after taxes	Shareholder's Equity	26.02	48.06	61.76	99.54	-20.57%	-37.95%
V	Inventory turnover ratio (in times)	Sales	Average Inventory	10.36	26.95	40.93	67.47	-34.14%	-39.34%
VI	Trade receivable turnover ratio (in times)	Total Sales	Average Accounts Receivable	2.96	6.72	6.30	11.48	6.66%	-45.12%
VII	Trade payables turnover ratio (in times)	Total Purchases	Average Trade Payables	1.36	4.92	4.32	4.28	13.76%	0.88%
VIII	Net Capital Turnover ratio (in times)	Net Sales	Average Working Capital	6.19	17.44	33.52	133.65	-47.97%	-74.92%
IX	Net Profit Ratio (in %)	Net Profit	Net Sales	12.90%	11.32%	9.59%	7.53%	18.02%	27.43%
X	Return on capital employed (in %)	Earning before Interest and taxes	Capital Employed	34.31%	65.43%	78.88%	119.72%	-17.05%	-34.11%
XI	Net Asset Value per share (Rs.)	Net Worth	Weighted Average Number of Equity Shares	17.03	9,148.90	4,660.59	1,782.06	96.30%	161.53%
XI	Net Asset Value per share (Rs.) (considering bonus impact for all periods)	Net Worth	Weighted Average Number of Equity Shares (considering bonus shares for all periods)	17.03	12.59	6.41	2.44	96.51%	162.44%

Reason for variance (where variance is more than 25% compared to the ratio of preceding year)

Variance for the Financial Year ended March 31, 2024

Sr.No of Ratio	Reason of variance
II	Improved debt equity ratio is due to reduction in payment of borrowed funds and also the equity is improved based on current year profit.
III	The company was able to generate higher profits with the same debt structure and hence the debt service coverage ratio has become positive.
VIII	The decreasing trend in the turnover ratio is on account of increase in credit period of trade receivables to boost sales and timely payment of trade payables to avoid interest on MSME dues and disallowances under the Income Tax Law.
V	The company is working towards achieving an optimum product mix which has led to an increase in inventory thereby decreasing in this ratio.

Variance for the Financial Year ended March 31, 2023

Sr.No of Ratio	Reason of variance
II	Improved debt equity ratio is due to reduction in payment of borrowed funds and also the equity is improved based on current year profit.
IV, X	The return on capital employed/equity has reduced in March 2023 since the capital employed was increased on account of previous year's profit but major funds were divested in acquisition of Property, Plant and Equipment which will yield productivity in a long run.
VIII	The decreasing trend in the turnover ratio is on account of increase in credit period of trade receivables to boost sales and timely payment of trade payables to avoid interest on MSME dues and disallowances under the Income Tax Law.
V	The company is working towards achieving an optimum product mix which has led to an increase in inventory thereby decreasing in this ratio.
VI	The company has been higher credit period to increase the sales leading to a rise in accounts receivable & thereby a fall in the overall ratio.
IX	The NAV per share has improved on account of net profit earned by the company during the year.

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

41 Reconciliation between the Audited Financial Statements and Restated Financial Statements

Shareholders' fund	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
As per Audited Financial Statements	3,091.72	2,287.22	1,181.42	452.54
Less : Provision for Gratuity liability	-	-	16.27	6.81
Less : Additional provision for income tax	-	-	-	0.21
As per Restated Financial Statements	3,091.72	2,287.22	1,165.15	445.51

Profit After Tax	As at 30 November, 2024	As at 31 March, 2024	As at 31 March, 2023	As at 31 March, 2022
As per Audited Financial Statements	804.50	1,105.80	728.88	450.48
Less : Gratuity expense as per actuarial valuation for current period	-	-	9.46	6.81
Less : Short Provision of Income tax adjusted	-	-	-	0.21
Add: Gratuity expense as per actuarial valuation for previous periods	-	16.27	-	-
As per Restated Financial Statements	804.50	1,122.08	719.63	443.45

42 Capitalisation Statement as per Para (D) of clause (11)(I) of Part A of Schedule VI to ICDR

Particulars	Pre Issue as at 30 November, 2024	As Adjusted for the proposed issue#
Borrowings		
Current Borrowings*	26.74	26.74
Non-current Borrowings* (including current maturities) (A)	-	-
Total Borrowings	26.74	26.74
Total Equity		
Equity Share Capital*	1,815.00	2,315.04
Reserves & Surplus*	1,276.72	5,877.09
Total Capital (B)	3,091.72	8,192.13
Ratio : Non-current borrowings/Total Equity (A)/(B)	-	-

*The terms shall carry the meaning as per Schedule III of the Companies Act, 2013 (as amended).

These amounts (As adjusted for the proposed issue) are estimates and actuals may vary post the share issue is concluded

(Formerly known as Influx Healthtech Private Limited)
Notes forming part of Restated Financial Statements

43 Additional Disclosure Requirements

No transactions or disclosures to report against the following disclosure requirements as notified by MCA pursuant to amended Schedule III of the Act:


- (a) Title deeds of immovable property not held in the name of the company
- (b) CWIP and Intangible under development ageing schedule
- (c) Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder
- (d) Wilful Defaulter
- (e) Scheme of arrangements in terms of section 230 to 237 of the Act
- (f) Utilisation of borrowed funds or share premium
- (g) Crypto Currency or Virtual Currency

44 Previous year figures have been re-grouped, re-classified where ever necessary

As per our attached report of even date.

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W


Vikas Goel
Partner
Membership. No.39287
Place : Mumbai
Date : 20/01/2025






Munir Chandniwala
(Managing Director)
DIN: 08459582
Place : Mumbai
Date : 20/01/2025



Ashish Shah
(Chief Financial Officer)
Place: Mumbai
Date : 20/01/2025



Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place : Mumbai
Date : 20/01/2025



Atul Shukla
(Company Secretary)
Membership Number : ACS46854
Place: Mumbai
Date : 20/01/2025